Table 2.
IPA pathway analysis of lithium effects
| Ingenuity canonical pathways | p value | Molecules | PIK3CG (n = 33) | PIK3R6 (n = 31) | PRKCB (n = 22) | NFKBIE (n = 13) | ITPR1 (n = 12) | JAK1 (n = 8) |
|---|---|---|---|---|---|---|---|---|
| Interferon signaling | 0.002 | IFIT1, JAK1, IFI6, MED14 | 1 | |||||
| Glucocorticoid receptor signaling | 0.002 | JAK1, TAF4, DUSP1, PIK3CG, ANXA1, NFKBIE, PIK3R6, SLPI, SMARCC1, FCGR1A, MED14 | 1 | 1 | 1 | 1 | ||
| p53 signaling | 0.003 | TP53INP1, JMY, PIK3CG, ADCK3, PIK3R6, TP53I3 | 1 | 1 | ||||
| VDR/RXR activation | 0.005 | CXCL10, SPP1, RUNX2, IL1RL1, PRKCB | 1 | |||||
| EGF signaling | 0.008 | JAK1, PIK3CG, PIK3R6, ITPR1 | 1 | 1 | 1 | 1 | ||
| UVA-induced MAPK signaling | 0.008 | TNKS, TIPARP, PIK3CG, PIK3R6, SMPD3 | 1 | 1 | ||||
| Hereditary breast cancer signaling | 0.010 | PMS2, FANCD2, PIK3CG, PIK3R6, SMARCC1, HDAC5 | 1 | 1 | ||||
| G-protein coupled receptor signaling | 0.010 | P2RY14, PDE7A, DUSP1, PIK3CG, NFKBIE, PIK3R6, ADORA3, ADORA2A, PRKCB | 1 | 1 | 1 | 1 | ||
| IL-17A signaling in airway cells | 0.012 | JAK1, PIK3CG, NFKBIE, PIK3R6 | 1 | 1 | 1 | 1 | ||
| Granulocyte adhesion and diapedesis | 0.013 | CXCL10, CLDN10, CCL23, IL1RL1, SDC3, HRH4, GLG1 | ||||||
| Neuropathic pain signaling in dorsal horn neurons | 0.013 | CAMK1, PIK3CG, PIK3R6, ITPR1, PRKCB | 1 | 1 | 1 | 1 | ||
| Role of NFAT in cardiac hypertrophy | 0.013 | CAMK1, PIK3CG, PIK3R6, RCAN3, ITPR1, HDAC5, PRKCB | 1 | 1 | 1 | 1 | ||
| Non-small cell lung cancer signaling | 0.013 | FHIT, PIK3CG, PIK3R6, ITPR1 | 1 | 1 | 1 | |||
| Erythropoietin signaling | 0.014 | PIK3CG, NFKBIE, PIK3R6, PRKCB | 1 | 1 | 1 | 1 | ||
| Huntington's disease signaling | 0.015 | TAF4, PIK3CG, CASP2, PIK3R6, ITPR1, PSME3, HDAC5, PRKCB | 1 | 1 | 1 | 1 | ||
| Chemokine signaling | 0.017 | CAMK1, PPP1R12B, PIK3CG, PRKCB | 1 | 1 | ||||
| Small cell lung cancer signaling | 0.017 | FHIT, PIK3CG, NFKBIE, PIK3R6 | 1 | 1 | 1 | |||
| IL-3 signaling | 0.017 | JAK1, PIK3CG, PIK3R6, PRKCB | 1 | 1 | 1 | 1 | ||
| fMLP signaling in neutrophils | 0.018 | PIK3CG, NFKBIE, PIK3R6, ITPR1, PRKCB | 1 | 1 | 1 | 1 | 1 | |
| IL-17 signaling | 0.018 | CXCL10, JAK1, PIK3CG, PIK3R6 | 1 | 1 | 1 | |||
| LPS-stimulated MAPK signaling | 0.019 | PIK3CG, NFKBIE, PIK3R6, PRKCB | 1 | 1 | 1 | 1 | ||
| NF-κB activation by viruses | 0.019 | PIK3CG, NFKBIE, PIK3R6, PRKCB | 1 | 1 | 1 | 1 | ||
| Prolactin signaling | 0.019 | PIK3CG, PIK3R6, PRLR, PRKCB | 1 | 1 | 1 | |||
| Aldosterone signaling in epithelial cells | 0.020 | DUSP1, PIK3CG, PIK3R6, ITPR1, DNAJB5, PRKCB | 1 | 1 | 1 | 1 | ||
| PDGF signaling | 0.023 | JAK1, PIK3CG, PIK3R6, PRKCB | 1 | 1 | 1 | 1 | ||
| 3-phosphoinositide biosynthesis | 0.024 | PPFIA1, ATP1A1, DUSP1, PIK3CG, PIK3R6, ILKAP | 1 | 1 | ||||
| Type 2 diabetes mellitus signaling | 0.025 | PIK3CG, NFKBIE, PIK3R6, SMPD3, PRKCB | 1 | 1 | 1 | 1 | ||
| CCR3 signaling in eosinophils | 0.025 | PPP1R12B, PIK3CG, PIK3R6, ITPR1, PRKCB | 1 | 1 | 1 | 1 | ||
| HMGB1 signaling | 0.027 | KAT7, KAT6B, KAT6A, PIK3CG, PIK3R6 | 1 | 1 | ||||
| Gustation pathway | 0.028 | P2RY2, TAS2R31, P2RY14, PDE7A, ITPR1 | 1 | |||||
| Role of pattern recognition receptors in recognition of bacteria and viruses | 0.032 | IRF7, C3, PIK3CG, PIK3R6, PRKCB | 1 | 1 | 1 | |||
| PI3K signaling in B lymphocytes | 0.034 | C3, PIK3CG, NFKBIE, ITPR1, PRKCB | 1 | 1 | 1 | 1 | ||
| Role of NFAT in regulation of the immune response | 0.034 | PIK3CG, NFKBIE, PIK3R6, RCAN3, ITPR1, FCGR1A | 1 | 1 | 1 | 1 | ||
| Endothelin-1 signaling | 0.035 | PLB1, PIK3CG, CASP2, PIK3R6, ITPR1, PRKCB | 1 | 1 | 1 | 1 | ||
| IL-12 signaling and production in macrophages | 0.041 | ALOX15, PIK3CG, APOA2, PIK3R6, PRKCB | 1 | 1 | 1 | |||
| Death receptor signaling | 0.041 | TNKS, TIPARP, CASP2, NFKBIE | 1 | |||||
| Production of nitric oxide and reactive oxygen species in macrophages | 0.042 | JAK1, PIK3CG, APOA2, NFKBIE, PIK3R6, PRKCB | 1 | 1 | 1 | 1 | 1 | |
| Glioma signaling | 0.045 | CAMK1, PIK3CG, PIK3R6, PRKCB | 1 | 1 | 1 | |||
Pathways differentially expressed with lithium treatment. IPA using the 301 genes with expression changes at FDR ≤0.40. Pathways are listed if p < 0.05 and they contained at least 4 genes with altered expression.